Kronos Bio IncNASDAQ:KRONNASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)
- LAST PRICE0.8743
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots0.8600/ 1
- Ask / Lots0.9390/ 24
- Open / Previous Close--- / 0.8743
- Day Range---
- 52 Week Range
- Volume401
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | KRON |
|---|---|---|
| 09:32 ET | 5167 | 0.8511 |
| 09:33 ET | 799 | 0.88 |
| 09:37 ET | 2116 | 0.8696 |
| 09:39 ET | 500 | 0.8747 |
| 09:44 ET | 100 | 0.869601 |
| 09:50 ET | 100 | 0.87475 |
| 09:51 ET | 4625 | 0.87 |
| 09:53 ET | 200 | 0.87 |
| 10:00 ET | 10219 | 0.87 |
| 10:02 ET | 700 | 0.87 |
| 10:04 ET | 100 | 0.87 |
| 10:06 ET | 1100 | 0.87 |
| 10:08 ET | 100 | 0.87 |
| 10:09 ET | 100 | 0.87 |
| 10:11 ET | 100 | 0.87 |
| 10:13 ET | 800 | 0.8778 |
| 10:15 ET | 983 | 0.87 |
| 10:27 ET | 100 | 0.8777 |
| 10:29 ET | 4289 | 0.8777 |
| 10:33 ET | 3410 | 0.8799 |
| 10:36 ET | 9720 | 0.891 |
| 10:42 ET | 600 | 0.9025 |
| 10:45 ET | 2000 | 0.8885 |
| 10:56 ET | 200 | 0.919 |
| 11:07 ET | 2151 | 0.9099 |
| 11:12 ET | 100 | 0.91 |
| 11:18 ET | 200 | 0.885 |
| 11:27 ET | 100 | 0.91 |
| 11:34 ET | 200 | 0.8977 |
| 11:48 ET | 100 | 0.9099 |
| 11:52 ET | 600 | 0.8975 |
| 12:10 ET | 100 | 0.899 |
| 12:12 ET | 3139 | 0.9 |
| 12:14 ET | 14820 | 0.9 |
| 12:19 ET | 100 | 0.91 |
| 12:21 ET | 1363 | 0.91 |
| 12:24 ET | 375 | 0.91 |
| 12:30 ET | 1332 | 0.911586 |
| 12:32 ET | 105 | 0.911586 |
| 12:39 ET | 100 | 0.92 |
| 12:50 ET | 100 | 0.9151 |
| 12:51 ET | 6400 | 0.9104 |
| 12:55 ET | 100 | 0.9151 |
| 01:02 ET | 5216 | 0.91 |
| 01:06 ET | 1663 | 0.9182 |
| 01:08 ET | 1300 | 0.91415 |
| 01:18 ET | 11091 | 0.9101 |
| 01:22 ET | 20100 | 0.9101 |
| 01:29 ET | 33138 | 0.886 |
| 01:36 ET | 2500 | 0.886 |
| 01:38 ET | 452 | 0.9 |
| 01:42 ET | 200 | 0.9044 |
| 01:44 ET | 648 | 0.9 |
| 02:02 ET | 291 | 0.886 |
| 02:07 ET | 133 | 0.8915 |
| 02:12 ET | 4302 | 0.868 |
| 02:14 ET | 200 | 0.863 |
| 02:16 ET | 100 | 0.8641 |
| 02:18 ET | 100 | 0.8641 |
| 02:20 ET | 100 | 0.8641 |
| 02:21 ET | 200 | 0.8632 |
| 02:23 ET | 491 | 0.863 |
| 02:25 ET | 100 | 0.863 |
| 02:27 ET | 100 | 0.8699 |
| 02:30 ET | 3400 | 0.863 |
| 02:32 ET | 200 | 0.855 |
| 02:34 ET | 200 | 0.855 |
| 02:36 ET | 100 | 0.8629 |
| 02:38 ET | 200 | 0.855 |
| 02:39 ET | 100 | 0.8629 |
| 02:41 ET | 475 | 0.855 |
| 02:43 ET | 277 | 0.8628 |
| 02:45 ET | 2600 | 0.855 |
| 02:48 ET | 400 | 0.855 |
| 02:50 ET | 200 | 0.8551 |
| 02:52 ET | 400 | 0.8551 |
| 02:54 ET | 100 | 0.855 |
| 02:56 ET | 200 | 0.855 |
| 02:57 ET | 200 | 0.855 |
| 02:59 ET | 200 | 0.855 |
| 03:01 ET | 100 | 0.855 |
| 03:03 ET | 500 | 0.855 |
| 03:06 ET | 100 | 0.8551 |
| 03:08 ET | 315 | 0.855 |
| 03:10 ET | 400 | 0.855 |
| 03:12 ET | 500 | 0.867 |
| 03:17 ET | 116 | 0.8653 |
| 03:21 ET | 3231 | 0.872 |
| 03:24 ET | 100 | 0.888 |
| 03:26 ET | 249 | 0.87 |
| 03:28 ET | 2347 | 0.8882 |
| 03:32 ET | 175 | 0.87 |
| 03:35 ET | 100 | 0.8883 |
| 03:42 ET | 1275 | 0.8791 |
| 03:46 ET | 375 | 0.87 |
| 03:50 ET | 300 | 0.87 |
| 03:53 ET | 1818 | 0.87 |
| 03:55 ET | 218 | 0.87 |
| 03:57 ET | 5071 | 0.8681 |
| 04:00 ET | 4247 | 0.8743 |
Nov 14, 2024
Kronos Bio Highlights Preclinical Data that Show p300 KAT Inhibitors Reduce Inflammation in an Oral Presentation at ACR Convergence 2024, from 4:02PM ET on Thursday Nov 14, 2024 by Dow Jones
4:02PM ET on Thursday Nov 14, 2024 by Dow JonesDJ Kronos Bio Cut to Neutral From Overweight by Piper Sandler, from 6:26AM ET on Thursday Nov 14, 2024 by Dow Jones
6:26AM ET on Thursday Nov 14, 2024 by Dow JonesDJ Kronos Bio Cut to Hold From Buy by TD Cowen, from 6:20AM ET on Thursday Nov 14, 2024 by Dow Jones
6:20AM ET on Thursday Nov 14, 2024 by Dow Jones
Nov 13, 2024
Kronos Bio Reports Third Quarter 2024 Financial Results and Corporate Update Including Plan to Evaluate Strategic Alternatives, from 4:05PM ET on Wednesday Nov 13, 2024 by Dow Jones
4:05PM ET on Wednesday Nov 13, 2024 by Dow Jones*DJ Kronos Bio 3Q Loss/Shr 23c >KRON, from 4:05PM ET on Wednesday Nov 13, 2024 by Dow Jones
4:05PM ET on Wednesday Nov 13, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Kronos Bio Inc | 52.7M | -0.6x | --- |
Cue Biopharma Inc | 62.0M | -1.1x | --- |
LAVA Therapeutics NV | 38.9M | -1.6x | --- |
Atara Biotherapeutics Inc | 60.1M | -0.4x | --- |
Dyadic International Inc | 49.2M | -7.6x | --- |
Tonix Pharmaceuticals Holding Corp | 38.2M | 0.0x | --- |
Company Information
Kronos Bio, Inc. is a biopharmaceutical company. The Company is focused on developing therapeutics that target the deregulated transcription that causes cancer and other serious diseases. It is developing KB-0742, its internally discovered oral cyclin dependent kinase 9 (CDK9) inhibitor, for the treatment of MYC-amplified and others transcriptionally addicted solid tumors. It has initiated the Phase 2 portion of its Phase 1/2 clinical trial for KB-0742. It is also developing KB-9558, which inhibits the lysine acetyltransferase (KAT) domain of p300, a critical node of the IRF4 TRN. IRF4 is a key transcription factor driver in multiple myeloma and KB-9558 selectively targets its activity. Its scientific focus is on developing medicines that target deregulated transcription, the hallmark of cancer and other serious diseases. Using its Small Molecule Microarray (SMM) platform or other approaches, it can generate and advance small molecule starting points into drug development candidates.
Contact Information
- Headquarters
- 1300 S. El Camino Real, Suite 400SAN MATEO, CA, United States 94402
- Phone
- 650-781-5200
- Fax
- 302-636-5454
Executives
- Non-Executive Independent Chairman of the Board
- Arie Belldegrun
- Director
- Norbert Bischofberger
- Chief Financial Officer, Chief Operating Officer, Chief Accounting Officer
- Deborah Knobelman
- Senior Vice President - Corporate Operations and Legal
- Allison Frisbee
- Senior Vice President - Research and Development
- Charles Lin
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $52.7M |
|---|---|
Revenue (TTM) | $9.9M |
Shares Outstanding | 60.3M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.84 |
EPS | $-1.44 |
Book Value | $2.70 |
P/E Ratio | -0.6x |
Price/Sales (TTM) | 5.3 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -943.60% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
